A Randomized, Double-Blind Placebo-Controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo.

Trial Profile

A Randomized, Double-Blind Placebo-Controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Octreotide (Primary)
  • Indications Carcinoid tumour; Neuroendocrine tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms RADIANT-2
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Apr 2017 Results of open-label extension phase (n=170) published in the Annals of Oncology
    • 07 Nov 2016 Results of a pharmacokinetic analysis published in the Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top